↓ Skip to main content

A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma

Overview of attention for article published in American Journal of Clinical Oncology: Cancer Clinical Trials, June 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

patent
64 patents
wikipedia
2 Wikipedia pages

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma
Published in
American Journal of Clinical Oncology: Cancer Clinical Trials, June 2007
DOI 10.1097/01.coc.0000256104.80089.35
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Germany 1 2%
Unknown 48 98%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Bachelor 7 14%
Student > Ph. D. Student 7 14%
Researcher 7 14%
Other 3 6%
Student > Master 3 6%
Other 6 12%
Unknown 16 33%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 8 16%
Medicine and Dentistry 7 14%
Agricultural and Biological Sciences 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Engineering 3 6%
Other 5 10%
Unknown 18 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2025.
All research outputs
#3,783,424
of 34,410,798 outputs
Outputs from American Journal of Clinical Oncology: Cancer Clinical Trials
#75
of 2,158 outputs
Outputs of similar age
#10,739
of 122,259 outputs
Outputs of similar age from American Journal of Clinical Oncology: Cancer Clinical Trials
#2
of 12 outputs
Altmetric has tracked 34,410,798 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,158 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,259 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.